Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (6) , 1562-1567
Abstract
No abstract availableKeywords
Funding Information
- Biomedical Laboratory Research and Development, VA Office of Research and Development
- National Institutes of Health (K24-AR02207, R01AR071653)
- U.S. Department of Veterans Affairs
- Health Services Research and Development
This publication has 21 references indexed in Scilit:
- The impact of skin damage due to cutaneous lupus on quality of lifeBritish Journal of Dermatology, 2013
- Cutaneous lupus erythematosus: Diagnosis and treatmentBest Practice & Research Clinical Rheumatology, 2013
- Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus ErythematosusJAMA Dermatology, 2013
- Quality of life in cutaneous lupus erythematosusJournal of the American Academy of Dermatology, 2011
- Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus ErythematosusArchives of Dermatology, 2011
- The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical resultsBritish Journal of Dermatology, 2008
- The Cutaneous Lupus Erythematosus Disease Area and Severity IndexArchives of Dermatology, 2008
- Cutaneous symptoms of dermatomyositis significantly impact patients' quality of lifeJournal of the American Academy of Dermatology, 2006
- The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus ErythematosusJournal of Investigative Dermatology, 2005
- DermatomyositisThe Lancet, 2000